Cargando…

Advanced Glycation End Products in the Pathogenesis of Psoriasis

Advanced glycation end products (AGEs) are extremely oxidant and biologically reactive compounds, which form through oxidation of sugars, lipids and amino acids to create aldehydes that bind covalently to proteins. AGEs formation and accumulation in human tissues is a physiological process during ag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papagrigoraki, Anastasia, Maurelli, Martina, del Giglio, Micol, Gisondi, Paolo, Girolomoni, Giampiero
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5713437/ https://www.ncbi.nlm.nih.gov/pubmed/29156622 http://dx.doi.org/10.3390/ijms18112471

Ejemplares similares

Advanced Glycation End Products and Psoriasis
por: Maurelli, Martina, et al.
Publicado: (2023)

Treatment Approaches to Moderate to Severe Psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2017)

Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2022)

Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis
por: Bellinato, Francesco, et al.
Publicado: (2022)

Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules
por: Bellinato, Francesco, et al.
Publicado: (2021)

The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis
por: Albanesi, Cristina, et al.
Publicado: (2018)

Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment
por: Gisondi, Paolo, et al.
Publicado: (2020)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016)

Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines
por: Bellinato, Francesco, et al.
Publicado: (2021)

Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities
por: Gisondi, Paolo, et al.
Publicado: (2020)

Annually Recurring Erythema Annulare Centrifugum: A New Case Series with Review of the Literature
por: Maurelli, Martina, et al.
Publicado: (2021)

Uncommon Non-Infectious Annular Dermatoses
por: Maurelli, Martina, et al.
Publicado: (2022)

Topographic Differential Diagnosis of Chronic Plaque Psoriasis: Challenges and Tricks
por: Gisondi, Paolo, et al.
Publicado: (2020)

Glomerular filtration rate in patients with psoriasis treated with etanercept
por: Gisondi, Paolo, et al.
Publicado: (2016)

Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy
por: Gisondi, Paolo, et al.
Publicado: (2014)

Immune Response to Vaccination in Patients with Psoriasis Treated with Systemic Therapies
por: Chiricozzi, Andrea, et al.
Publicado: (2020)

Pruritus as a Distinctive Feature of Type 2 Inflammation
por: Garcovich, Simone, et al.
Publicado: (2021)

The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments
por: Gisondi, Paolo, et al.
Publicado: (2020)

Alopecic and aseptic nodules of the scalp: A new case with a systematic review of the literature
por: Bellinato, Francesco, et al.
Publicado: (2021)

Clinical Characteristics of Patients with Pustular Psoriasis: A Single-Center Retrospective Observational Study
por: Gisondi, Paolo, et al.
Publicado: (2022)

Increased red blood cell distribution width in patients with plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2021)

Management of Moderate to Severe Psoriasis in Patients with Metabolic Comorbidities
por: Gisondi, Paolo, et al.
Publicado: (2015)

Central Pain Sensitization in Patients with Chronic Plaque Psoriasis
por: Bellinato, Francesco, et al.
Publicado: (2023)

Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis
por: Maurelli, Martina, et al.
Publicado: (2023)

Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
por: Gisondi, Paolo, et al.
Publicado: (2022)

Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review
por: Girolomoni, Giampiero, et al.
Publicado: (2023)

Psychological Stress and Salivary Cortisol Levels in Patients with Plaque Psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2021)

Pharmacological Control of Receptor of Advanced Glycation End-Products and its Biological Effects in Psoriasis
por: Mezentsev, A. V., et al.
Publicado: (2013)

Targeting IL-4 for the Treatment of Atopic Dermatitis
por: Chiricozzi, Andrea, et al.
Publicado: (2020)

Endogenous advanced glycation end products in the pathogenesis of chronic diabetic complications
por: Mengstie, Misganaw Asmamaw, et al.
Publicado: (2022)

Cutaneous Adverse Reactions to SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis
por: Bellinato, Francesco, et al.
Publicado: (2022)

Dietary Advanced Glycation End Products and Aging
por: Luevano-Contreras, Claudia, et al.
Publicado: (2010)

Toxicity of advanced glycation end products (Review)
por: Kuzan, Aleksandra
Publicado: (2021)

Advanced Glycation End Products in Health and Disease
por: Reddy, V. Prakash, et al.
Publicado: (2022)

The Role of Advanced Glycation End Products on Dyslipidemia
por: Vekic, Jelena, et al.
Publicado: (2023)

Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review
por: Dal Bello, Giacomo, et al.
Publicado: (2020)

Advanced Glycation End Products and Diabetic Complications
por: Singh, Varun Parkash, et al.
Publicado: (2014)

Overview of Atopic Dermatitis in Different Ethnic Groups
por: Chiricozzi, Andrea, et al.
Publicado: (2023)

Coexistence of scleromyxedema and Sneddon syndrome
por: Furci, Antonio, et al.
Publicado: (2021)

Advanced Glycation End-Products in Skeletal Muscle Aging
por: Olson, Lucas C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4ejcolcgj8tba5vlrhkmcvvh2m